SpringWorks Therapeutics Inc.

Four drugs with an orphan designation – Aucatzyl (obecabtagene autoleucel), Blenrep (belantamab mafodotin), Ezmekly (mirdametinib) and Maapliv (amino acids) – are among the 10 new products on track fo

The European Medicines Agency is this week deciding whether to recommend pan-EU marketing authorization for a number of new medicines, including obecabtagene autoleucel (obe-cel), Autolus Therapeutics

In the top alliance by deal value, ABL Bio entered a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio’s blood-brain barrier shu

After a couple of months of talks, Merck KGaA has inked a deal to buy SpringWorks Therapeutics which will expand its presence in the US and sharpen the firm’s focus in rare diseases and cancer. The pu